ChromaDex Corporation (CDXC)
Company Description
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products.
The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.
It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function.
In addition, it offers phytochemical reference standards, and other research and development services.
The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.
ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 106 |
CEO | Robert N. Fried |
Contact Details
Address: 10900 Wilshire Blvd, Suite 600 Los Angeles, California 90024 United States | |
Phone | 310-388-6706 |
Website | chromadex.com |
Stock Details
Ticker Symbol | CDXC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001386570 |
CUSIP Number | 171077407 |
ISIN Number | US1710774076 |
Employer ID | 26-2940963 |
SIC Code | 2833 |
Key Executives
Name | Position |
---|---|
Frank Louis Jaksch Jr. | Co-Founder and Chairman |
Robert N. Fried | Chief Executive Officer and Director |
Brianna Gerber | Chief Financial Officer |
Dr. Andrew Shao Ph.D. | Senior Vice President of Global Regulatory and Scientific Affairs |
Heather Van Blarcom | Senior Vice President of Legal and Corporate Secretary |
Alex Worsham | Vice President of Global Marketing and Communications |
David Kroes | Senior Vice President of People Matters |
Chu Yan | Managing Director of Asia Pacific |
Jason Campbell | Senior Vice President of Business Development |
Kendall Knysch | Head of Media Relations and Partnerships |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 6, 2024 | 8-K | Current Report |
Mar 6, 2024 | 10-K | Annual Report |
Dec 13, 2023 | 8-K | Current Report |
Nov 8, 2023 | 8-K | Current Report |
Nov 8, 2023 | 10-Q | Quarterly Report |
Sep 7, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Aug 9, 2023 | 8-K | Current Report |
Aug 9, 2023 | 10-Q | Quarterly Report |
Jul 6, 2023 | 424B5 | Filing |
Jul 5, 2023 | EFFECT | Notice of Effectiveness |